Safety and tolerability of a DNA-based influenza vaccine composed of a combination of two different H1 HA plasmids administered ID followed by electroporation in healthy elderly adult subjects Day 0 through Month 12 [clinicaltrials_resource:21c9991ed2761f552a9499a3ba4510f6]
Frequency and severity of local and systemic reactogenicity signs and symptoms, adverse events and serious adverse events
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Safety and tolerability of a DNA-based influenza vaccine composed of a combination of two different H1 HA plasmids administered ID followed by electroporation in healthy elderly adult subjects Day 0 through Month 12 [clinicaltrials_resource:21c9991ed2761f552a9499a3ba4510f6]
Frequency and severity of local and systemic reactogenicity signs and symptoms, adverse events and serious adverse events
Bio2RDF identifier
21c9991ed2761f552a9499a3ba4510f6
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:21c9991ed2761f552a9499a3ba4510f6
measure [clinicaltrials_vocabulary:measure]
Safety and tolerability of a D ...... healthy elderly adult subjects
time frame [clinicaltrials_vocabulary:time-frame]
Day 0 through Month 12
description
Frequency and severity of loca ...... nts and serious adverse events
identifier
clinicaltrials_resource:21c9991ed2761f552a9499a3ba4510f6
title
Safety and tolerability of a D ...... ubjects Day 0 through Month 12
@en
type
label
Safety and tolerability of a D ...... 9991ed2761f552a9499a3ba4510f6]
@en